Mydecine Innovations Group Inc.
MYCOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $0 | $1 | $4 | $4 |
| G&A Expenses | $1 | $7 | $10 | $15 |
| SG&A Expenses | $2 | $8 | $10 | $15 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $2 | $3 |
| Operating Expenses | $2 | $9 | $16 | $22 |
| Operating Income | -$2 | -$9 | -$16 | -$22 |
| % Margin | – | – | – | -294,931% |
| Other Income/Exp. Net | -$1 | -$12 | -$0 | -$1 |
| Pre-Tax Income | -$3 | -$21 | -$16 | -$24 |
| Tax Expense | $0 | $0 | -$5 | $0 |
| Net Income | -$3 | -$21 | -$12 | -$29 |
| % Margin | – | – | – | -385,658.6% |
| EPS | -0.053 | -0.68 | -1.37 | -6.17 |
| % Growth | 92.2% | 50.4% | 77.8% | – |
| EPS Diluted | -0.053 | -0.68 | -1.37 | -6.17 |
| Weighted Avg Shares Out | 60 | 31 | 9 | 5 |
| Weighted Avg Shares Out Dil | 60 | 31 | 9 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2 | -$9 | -$16 | -$23 |
| % Margin | – | – | – | -308,854.5% |